^
Association details:
| Biomarker: | MRD4 negative |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | NVG-111 (CD3 agonist, ROR1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1810 First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
Published date:
11/03/2022
Excerpt:
This multi-center, open-label, phase I study is evaluating NVG-111 in relapsed/refractory CLL and MCL subjects who have received ≥2 prior systemic therapies….Objective clinical responses were observed in 66% of subjects and included 2 MRD4 negative clinical remissions (CR). These two subjects remained in MRD4 negative CRs at 6 months after completion of treatment....Early data shows that NVG-111 is generally well tolerated with a predictable and manageable safety profile. Promising evidence of efficacy was observed which appears to be durable in two subjects with MRD4 negative CR.
DOI:
https://doi.org/10.1182/blood-2022-169658
